Skip to main content

Table 1 Baseline characteristics of the study patients by site and treatment groups, Togo, 2021–2022

From: Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine and prevalence of molecular markers of anti-malarial drug resistance in children in Togo in 2021

Characteristics

Kouvé

Anié

ALa

DPb

ALa

DPb

Number of patients

97

95

82

83

Males (%)

44/97 (45.4)

49/95 (51.6)

38/82 (46.4)

49/83 (59.0)

Age (years)

    

 Mean (± SDc)

2.9 (± 1.3)

2.9 (± 1.3)

3 (± 1.3)

2.8 (± 1.3)

 Range (min–max)

0.5–4.9

0.6–4.9

0.5–4.9

0.5–4.9

Temperature (°C)

    

 Mean (± SDc)

38.4 (± 1.2)

38.5 (± 1.3)

38.1 (± 0.7)

38 (± 0.7)

Haemoglobin level (g/dL)

    

 Mean (± SDc)

10.3 (± 1.6)

9.8 (± 1.8)

10.0 (± 1.4)

9.4 (± 1.7)

Parasitaemia (/µL), day 0

    

 Geometric mean

38,161*

39,016**

14,527*

9,828**

 Range (min–max)

2,088–363,230

2,004–548,400

2,114–184,667

2,024–339,000

  1. aartemether-lumefantrine,
  2. bdihydroartemisinin-piperaquine,
  3. cstandard deviation
  4. *Patients in Kouvé had significantly higher parasite density compared to Anié for AL (p < 0.0001) treated groups
  5. **Patients in Kouvé had significantly higher parasite density compared to Anié for DP (p < 0.0001) treated groups